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Case report
A  54-yeAr-old  CAuCAsiAn  womAn  presented  to  our 
emergency department with a 3-week history of product-
ive cough, shortness of breath and malaise. Four weeks 
before, she had visited her family physician with ear pain 
and nasal fullness. Acute sinusitis was diagnosed, and 
she was prescribed a 10-day course of levofloxacin, along 
with triamcinolone nasal spray. However, she developed 
increasing shortness of breath on exertion, followed by 
fever, chills, rigours and intermittent night sweats.
She was reevaluated by her family physician 3 days 
before presentation and was prescribed clarithromycin 
(500  mg  twice  daily)  for  a  diagnosis  of  community- 
acquired  pneumonia;  however,  her  symptoms  pro-
gressed and she came to our emergency department for 
further evaluation. 
The patient resided with her husband and 1 adult child. 
As director of a homeless shelter program, she inspected 
shelters on a weekly basis. A tuberculin skin test per-
formed 8 years earlier was negative. The patient denied 
all risk factors for HIV infection. She was a lifelong non-
smoker and consumed 5 standard alcoholic beverages 
per week. She denied sick contacts and allergies to ani-
mals and did not have a significant travel history. 
Her medical history was significant for allergic rhin-
itis,  recurrent  sinusitis  and  asthma.  Current  asthma 
treatment  included  inhaled  steroids  (fluticasone), 
long- and short-acting β2-agonists (salbutamol and sal-
meterol) and a leukotriene receptor antagonist (montel-
ukast). She began taking montelukast 8 months before 
her  presentation  and  had  required  systemic  cortico-
steroids for asthma exacerbations on 2 separate occa-
sions in the 6 months preceding her presentation. Her 
medications on presentation were her asthma therapy, 
clarithromycin and triamcinolone nasal spray. She had 
an anaphylactic allergy to lactose. There was no family 
history of respiratory or inflammatory disease. 
On examination, the patient appeared thin and was in 
moderate respiratory distress at rest. She was febrile with 
a temperature of 38oC, she had a pulse rate of 104 beats/
min, her blood pressure was 139/77 mm Hg, her respira-
tory rate was 34 breaths/min and she had a decreased 
oxygen saturation of 92% on room air. Auscultation of 
the chest revealed decreased breath sounds throughout 
both lung fields, with crackles heard predominantly in 
the left and right upper lobes. Examination of the pre-
cordium revealed normal heart sounds and the presence 
of a grade II/VI systolic ejection murmur heard best at 
the base of the heart. She did not have a rash. Findings of 
the rest of the physical examination were normal.
Blood-work findings included a hemoglobin level of 
146 (normal range 138–175) g/L and a white blood cell 
count of 29.3 (normal 4.5–11) × 109/L, with 16.7 × 109/L 
(57%) eosinophils (normal 0%–3%), 37.8% neutrophils 
(normal  50%–62%),  3%  lymphocytes  (normal  25%–
40%), 2% monocytes (normal 3%–7%) and no basophils 
(normal 0%–1%) (Fig. 1). Arterial blood gas analysis re-
vealed a pH of 7.49 (normal 7.35–7.45), a partial pres-
sure of carbon dioxide (PCO2) of 35 (normal 35–45) mm 
Hg, a partial pressure of oxygen (PO2) of 57 (normal 
80–100) mm Hg and a bicarbonate level of 27 (normal 
22–26) mmol/L. Renal function was normal. The lac-
tic acid dehydrogenase level was elevated (357 [normal 
100–195] IU/L) and the C reactive protein level was very 
high (136 [normal < 10] mg/L). To investigate the pos-
sibility  of  rheumatologic  lung  disease,  including  Weg-
ener’s granulomatosis and Goodpasture’s syndrome, we 
examined  the  concentration  of  rheumatoid  factor  and 
the antinuclear antibody titer, and we tested for anti-
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basement  membrane  antibodies;  all  test  results  were 
negative.  Immunoglobulin  titers  were  normal,  aside 
from an elevated IgE (1280 [normal < 175] IU/L). A chest 
radiograph revealed bilateral peripheral pulmonary in-
filtrates with central sparing (Fig. 2).
The physical examination and radiography findings 
suggested  the  possibility  of  pneumonia.  Tuberculosis 
warranted consideration given the patient’s occupation-
al history and the insidious nature of her illness; how-
ever, her history of asthma and pulmonary infiltrates 
placed Churg–Strauss syndrome high on the differential 
diagnosis (Box 1).1
Broad-spectrum  empirical  treatment  with  ceftriax-
one and clarithromycin was initiated, and montelukast 
therapy was discontinued because of the possible associ-
ation between montelukast therapy and the development 
of  Churg–Strauss  vasculitis  in  patients  with  asthma. 
Despite antibiotic therapy, the patient remained febrile 
(temperature 39oC), tachycardic (110 beats/minute) and 
tachypneic (40 breaths/min) and she required 35% oxy-
gen to maintain oxygen saturation above 90%. Cultures 
of  blood,  sputum,  urine  and  stool  yielded  no  growth. 
The  results  of  staining  of  3  sputum  specimens  were 
negative for acid-fast bacilli, as was an enzyme-linked 
immunosorbent  assay  (ELISA)  conducted  on  a  urine 
sample to detect Legionella antigen. 
Contrast computed tomography of the chest revealed 
mild  mediastinal  lymphadenopathy,  with  the  right 
paratracheal lymph nodes measuring 1.4 cm in diam-
eter. There were small bilateral pleural effusions and ex-
tensive air-space disease with scattered consolidation in 
all lobes and confluent consolidation in the upper lobes. 
There was no evidence of pulmonary embolus, cavita-
tion, loculation or pleural irregularity (Fig. 3).
On her third day in hospital, the patient complained 
of increasing shortness of breath and retrosternal chest 
heaviness  at  rest.  Her  troponin  T  level  was  elevated 
(0.94  μg/L),  her  creatine  phosphokinase  (CPK)  level 
was 290 (normal 5–160) IU/L, and the CPK MB frac-
tion  was  9%.  An  electrocardiogram  revealed  anterior 
ST segment elevation, and mild PR segment depression 
suggested a component of ischemia or pericarditis. An 
echocardiogram showed normal left ventricular size, an 
ejection fraction of 50% (normal > 60%), anterior wall 
hypokinesis,  trace  pericardial  effusion  and  no  valvul-
ar  abnormalities.  These  echocardiography  findings  in 
conjunction with a negative screen for anti-neutrophil 
cytoplasmic antibodies and high eosinophil count sug-
gested myocardial disease secondary to Churg–Strauss 
or hypereosinophilic syndrome.
Open Medicine 2010;4(4):e188
Box 1:  American College of Rheumatology 1990 criteria for 
the classifi  cation of Churg–Strauss syndrome. The diagnosis 
requires at least 4 of 6 of the following criteria:1
•	 Asthma:	History	of	wheezing	or	diﬀ 	use	high-pitched	expiratory	
rhonchi
•	 Eosinophilia:	Eosinophilia	>10%	on	diﬀ 	erential	white	blood	cell	
count
•	 Mono-	or	poly-neuropathy	attributable	to	systemic	vasculitis
•	 Migratory	or	transitory	pulmonary	infi 	ltrates
•	 Paranasal	sinusitis
•	 Biopsy	containing	a	blood	vessel	showing	the	accumulation	of	
eosinophils	in	extravascular	area
Figure 1: Peripheral blood film showing eosinophilia.
 
Figure 2: Chest radiograph (anterior-posterior view).Our  patient  consented  to  bronchoscopy,  which  re-
vealed no discrete lesions. Bronchial lavage fluid con-
tained 92% eosinophils (normal < 1%), 6% lymphocytes 
(normal 10%–20%), 0% neutrophils (normal 70%–80%) 
and 2% histiocytes. There were no malignant cells. The 
results  of  gram  and  acid-fast  staining  were  negative. 
Transbronchial biopsy was deferred as no coagulation 
profile was available. 
Bone-marrow  aspiration  and  biopsy  were  also  per-
formed; the bone marrow exhibited 45%–55% eosinophil-
ic hyperplasia (normal 1.5%), with normal erythropoiesis 
and  granulopoiesis.  There  was  no  evidence  of  nuclear 
atypia, granulomata, lymphoid aggregates or metastatic 
cells (Fig. 4). 
Because of the suspicion that the patient might have 
Churg–Strauss syndrome, a computed tomography scan 
of  the  paranasal  sinuses  was  performed  and  revealed 
minor mucosal thickening at the floor of the maxillary 
sinuses.
Given the patient’s systemic eosinophilia, the multi-
system involvement with a focus on pulmonary symptoms 
at the time she presented to the emergency department, 
her history of asthma and the lack of response to antibiot-
ic therapy, the 2 leading working diagnoses were Churg–
Strauss syndrome and hypereosinophilic syndrome. 
Antibiotics  were  discontinued  and  the  patient  was 
given 50 mg of prednisolone once daily. Her cough, fever 
and shortness of breath resolved over the next 5 days. 
Her white blood cell count and white blood cell differ-
ential  returned  to  normal.  A  repeat  chest  radiogram 
demonstrated improvement in the bilateral lung opaci-
ties,  and  a  repeat  electrocardiogram  was  negative  for 
ischemia. 
The patient was discharged home with instructions 
to slowly taper her dose of prednisolone to 20 mg. The 
presumptive  diagnosis  at  the  time  of  discharge  was 
Churg–Strauss syndrome. An echocardiogram taken on 
an outpatient basis demonstrated resolution of wall mo-
tion abnormalities. Cytogenetic studies to investigate the 
possibility  of  hypereosinophilic  syndrome  were  nega-
tive for the F1P1L1-PDGFR-alpha mutation, although it 
should be noted that the incidence of a positive cytogen-
etic  test  in  patients  with  hypereosinophilic  syndrome 
varies  between  4%  and  60%.2  A  positive  cytogenetic 
study, however, does predict success in treatment with 
imatinib, with literature showing 60%–80% remission 
rates in this population.3–6 The interleukin-5 level, which 
is  sometimes  elevated  in  a  subgroup  of  patients  with 
hypereosinophilia with clonal disease, was also normal 
in this patient. This further suggested that other bio-
logical treatments, such as anti-interleukin-5 antibody 
therapy, which is currently being investigated in a clin-
ical trial, would also probably not be beneficial.
Three months after discharge the patient developed 
recurrent respiratory symptoms and an increase in her 
blood eosinophil count. She was given hydroxyurea, and 
her eosinophil count decreased into the normal range. 
Her  prednisolone  intake  was  tapered  to  10  mg/day. 
Cardiac magnetic resonance imaging revealed a mildly 
dilated left ventricle with normal ejection fraction and 
systolic  function.  The  other  cardiac  structures  were 
normal. Repeat chest radiography and abdominal ultra-
sound results were unremarkable.
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Figure 3: Computed tomogram of the chest at the level  
of the carina.
 
Figure 4: Bone marrow biospsy showing eosinophilia.Discussion
This  patient  presented  with  signs  and  symptoms  of  a 
common medical condition: community-acquired pneu-
monia. The lack of response to appropriate treatment for 
pneumonia was the initial clinical clue that the differen-
tial diagnosis needed to be expanded. Her occupational 
history and non-resolving symptoms raised the possi-
bility of pulmonary tuberculosis as a cause of infection; 
however, other diagnoses such as inflammatory condi-
tions  like  Churg–Strauss  syndrome  and  drug-induced 
lung disease were also considered given her history of 
asthma and use of leukotriene antagonists. In addition, 
the  significant  peripheral  eosinophilia  raised  the  sus-
picion of an underlying hematologic condition such as 
hypereosinophilic syndrome. Box 2 shows the diagnos-
tic  criteria  of  hypereosinophilic  syndrome,7  and  Table 
1  shows  treatment  strategies  for  Churg–Strauss  and 
hypereosinophilic syndromes. 
Eosinophilic  disorders  are  rare  and  challenging  to 
diagnose. Earlier classifications of eosinophilic diseases 
were based on the site of eosinophilic infiltration; other 
classifications are based on the actual number of blood 
eosinophils present. However, recent research into the 
pathogenesis of eosinophilia has led to a simplified ap-
proach to the diagnosis of this disorder.8 The new clas-
sification hinges on a simple question: Is the primary 
cause of eosinophilia intrinsic (i.e., located within the 
eosinophils  themselves)  or  extrinsic  (i.e.,  outside  the 
eosinophil lineage)?8 Intrinsic eosinophilic disorders are 
hematologic disorders affecting either the pluripotent or 
multipotent stem cells. Extrinsic eosinophilic disorders 
are triggered by cytokine release and subsequent stimu-
lation of eosinophils or their precursors.
Intrinsic  eosinophilic  disorders  are  generally  char-
acterized  by  chromosomal  abnormalities  involving 
tyrosine kinase function and either fibroblast- or plate-
let-derived  growth  factors.  The  abnormality  involving 
platelet-derived growth factors manifests as a clonal dis-
order involving the pluripotent stem cells and is identi-
fied using molecular or cytogenetic tests to identify an 
F1P1L1-PDGFR-alpha  mutation.  These  tests  are  now 
commercially available. There are 2 basic forms of test-
ing: (1) molecular genetic testing with reverse-transcript-
ase  polymerase  chain  reaction  to  recognize  abnormal 
RNA transcripts and (2) karyotyping and identification 
of the interstitial deletion on chromosome 4 using 2- or 
3-colour fluorescence in situ hybridization.9 The utility 
of this type of cytogenetic testing can most commonly 
be seen in chronic myelocytic leukemia (CML). CML is 
associated  with  the  Philadelphia  chromosome  and  its 
fusion protein product BCR-ABL1 tyrosine kinase. The 
overexpression of this protein leads to unregulated pro-
liferation of clonal myeloid cells in CML. In addition, the 
identification of BCR-ABL1 allowed for the discovery and 
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Table 1:  Epidemiologic and treatment di￿  erences between Churg–Strauss syndrome and hypereosinophilic 
syndrome
Feature Churg–Strauss syndrome Hypereosinophilic syndrome
Epidemiology •	 Prevalence	unknown;	10%	of	all	vasculitis	patients	
have	Churg–Strauss	syndrome
•	 Age	at	diagnosis:	approx.	40	years	
•	 40%-60%	of	cases	are	ANCA	positive
•	 Rare;	prevalence	unknown
•	 Age	at	diagnosis:	20–50	years	
•	 Association	with	FIP1L1-PDGFR-alpha	mutation
Treatment 1st	line:
•	 Glucocorticoids	and	cyclophosphamide
Maintenance:
•	 Azathioprine
•	 Methotrexate
•	 Inhaled	glucocorticoids
Refractory	disease:
•	 Mycophenolate	mofetil
•	 Intravenous	immunoglobulin
•	 Hydroxyurea
•	 Rituximab
•	 Interferon-alpha
•	 Anti-immunoglobulin	E	antibodies
•	 Anti-interleukin	5	antibodies
1st	line:
•	 Glucocorticoids
2nd	line:
•	 Imatinib	(if	cytogenetics	+ve)
•	 Hydroxyurea	(if	cytogenetics	–ve)
3rd	line	(clinical	trials):
•	 Interferon-alpha
•	 Anti-interleukin	5	antibodies
•	 Anti-CD52	antibodies
ANCA	=	anti-neutrophil	cytoplasmic	antibodies
Box 2:  Diagnostic criteria for hypereosinophilic syndrome 
•	 Blood	eosinophilia	of	>1500/μL	present	for	more	than	6	months
•	 No	other	apparent	causes	for	eosinophilia,	such	as	parasitic		
infection	or	allergic	disease
•	 Signs	or	symptoms	(or	both)	of	eosinophil-mediated	end-organ	
dysfunctionsuccessful use of small molecule inhibitors like imatinib 
mesylate to induce remission of CML. 
Extrinsic eosinophilic disorders are numerous. They 
are  subdivided  into  T-cell-mediated  and  tumour-cell-
mediated eosinophilic disorders.8 T-cell-mediated eosin-
ophilia  can  be  due  to  allergic  diseases  like  bronchial 
asthma or it can be due to autoimmune diseases such as 
Churg–Strauss syndrome. In both cases, interleukin-5 
is  responsible  for  mediating  eosinophil  differentia-
tion,  activation  and  survival.10  Eosinophils  contribute 
to  worsening  inflammation,  tissue  damage  and  organ 
dysfunction. They have also been implicated in tissue 
remodeling following an acute inflammatory reaction.11 
The  negative  cytogenetic  testing  in  this  patient’s  case 
does not eliminate the possibility of an eosinophilic dis-
order; rather, it pushes the clinician to consider other 
diagnoses.
Idiopathic hypereosinophilic syndrome is diagnosed 
on  the  basis  of  clinical  and  pathologic  criteria  and  is 
characterized by blood eosinophilia that is neither sec-
ondary  nor  clonal  in  nature.12  The  diagnosis  requires 
documentation of both target end-organ damage and an 
absolute eosinophil count of 1.5 × 109/L or higher for at 
least 6 months.13 By definition, testing must demonstrate 
a lack of any known molecular or cytogenetic markers, 
and bone marrow histology must not display evidence of 
abnormal populations of mast cells, monocytosis, trilin-
eage myeloproliferation or dysplasia.14 Specific therapy 
for hypereosinophilic syndrome includes high-dose ster-
oids as first-line treatment, with hydroxyurea added if 
remission is not achieved.
Classical medical training pushed our diagnosis to-
ward Churg–Strauss syndrome, in part because of the 
prominence of pulmonary involvement. However, as we 
assessed the spectrum of organs involved, an organ-fo-
cused classification of our patient’s illness seemed less 
appropriate  and  we  altered  our  diagnostic  process  to 
consider idiopathic hypereosinophilic syndrome. 
The traditional method of categorizing diseases ac-
cording to clinical features is in flux as we learn more 
about the genetic basis of many conditions. When gen-
etic markers are present, they aid the clinician in making 
a diagnosis; when they are not, the clinician must rely 
on clinical and pathologic features to make a diagnosis. 
Our increasing understanding of underlying genetic ab-
normalities has sparked a revolution in the diagnoses 
of many blood dyscrasias. For example, the discovery of 
the Philadelphia chromosome has dramatically changed 
the  way  we  diagnose  conditions  involving  neoplastic 
transformation,  and  research  on  JAK2  mutations  has 
affected  the  diagnosis  of  myeloproliferative  disorders. 
Historically,  blood  disorders  were  classified  using  an 
operational system based on cell lines (i.e., myeloid v. 
lymphoid),  cell  morphology  and  the  presence  of  blast 
cells (to delineate acute from chronic conditions). In the 
last  decade,  a  classification  system  based  on  genetics 
and immunology has increasingly been used for blood 
disorders. Although physicians are trained to recognize 
syndromes on the basis of clinical and pathologic fea-
tures, the reality is that many patients with blood dys-
crasias are asymptomatic or, in rare cases, have normal 
peripheral  blood  films.  In  these  cases,  molecular  and 
cytogenetic testing becomes the mainstay of diagnosis; 
these forms of testing also provide confirmation of the 
presence of a disease in patients who have a high clinical 
pre-test probability of having the disease. 
Epigenetics is the study of heredity not related to the 
DNA  sequence.  It  examines  the  relationship  between 
genetic background, the environment and disease. Epi-
genetic processes can modify or affect potentially dele-
terious  genes.15  The  epigenetic  modification  of  DNA 
through methylation and covalent modifications of nu-
cleosome histone proteins underly much of the reclassifi-
cation of blood dyscrasias. Unlike mutations in the DNA 
sequence, epigenetic changes are, by definition, revers-
ible,  which  offers  the  exciting  hope  that  they  may  be 
modified through therapy.15  
For now, our patient’s condition will carry the label of 
idiopathic hypereosinophilic syndrome, unless further 
developments in molecular testing necessitate a change 
in diagnosis. We will continue to treat her with immuno-
suppressive therapy as we await a deeper understanding 
of the true intrinsic or extrinsic trigger for her symptoms.
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